Nymox Pharmaceutical Corporation NYMX is pleased to announce the completion of enrollment for Study NX02-0020, one of the Company's Phase 3 studies of NX-1207 for benign prostatic hyperplasia (BPH). The NX02-0020 study started in July 2011 and involved men who had previously participated in one of the earlier NX-1207 studies for BPH and in the current trial wished an open label injection of NX-1207.
A recent Safety Committee meeting update on the trial indicated no significant safety concerns to date. Recruitment of new participants for this ongoing study is now completed. Efficacy results for Study NX02-0020 are expected near the end of this year.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in